Shawn Cross sold $303k of PCRX
Chief Financial Officer at Pacira BioSciences, Inc.. 12,059 shares at an average of $25.09, traded Apr 20, 2026, filed Apr 22, 2026.
Score components
- +22RoleCFO
- +14Trade size$303k at market
- +5Share of holdings soldSold 11% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -6.2%, 3m +2.9%, 6m -.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001628280-26-026669, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Apr 20, 2026 | MOption exercise Common Stock10b5-1 | +7,714 | $16.45 | $127k | 113,055 | Apr 22, 2026 |
| Apr 20, 2026 | SOpen-market sale Common Stock10b5-1 | -7,714 | $25.14 | $194k | 105,341 | Apr 22, 2026 |
| Apr 21, 2026 | MOption exercise Common Stock10b5-1 | +2,845 | $16.45 | $47k | 108,186 | Apr 22, 2026 |
| Apr 21, 2026 | SOpen-market sale Common Stock10b5-1 | -2,845 | $25.01 | $71k | 105,341 | Apr 22, 2026 |
| Apr 22, 2026 | MOption exercise Common Stock10b5-1 | +1,500 | $16.45 | $25k | 106,841 | Apr 22, 2026 |
| Apr 22, 2026 | SOpen-market sale Common Stock10b5-1 | -1,500 | $25.01 | $38k | 105,341 | Apr 22, 2026 |
| Apr 20, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -7,714 | $0.00 | $0 | 167,286 | Apr 22, 2026 |
| Apr 21, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -2,845 | $0.00 | $0 | 164,441 | Apr 22, 2026 |
| Apr 22, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -1,500 | $0.00 | $0 | 162,941 | Apr 22, 2026 |
Related signals
Other insiders at Pacira BioSciences, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| Pro nowfree Oct 16, 2026 | Pacira BioSciences, Inc. | Lauren Riker Senior Vice President, Finance | $218k 6,000 shares | -9% | |
| 3Weak | Pacira BioSciences, Inc. | Jonathan Slonin Chief Medical Officer | $71k 3,040 shares | -1% | |
| 14Weak | Pacira BioSciences, Inc. | Lauren Riker Senior Vice President, Finance | $144k 6,115 shares | -9% | |
| 16Weak | Pacira BioSciences, Inc. | Kristen Williams Chief Administrative Officer | $228k 10,259 shares | -6% | |
| 7Weak | Pacira BioSciences, Inc. | Shawn Cross Chief Financial Officer | $326k 12,941 shares | -11% | |
| 23Weak | Pacira BioSciences, Inc. | Mark Froimson director | $11k 500 shares | -2% | |
| 11Weak | Pacira BioSciences, Inc. | Jonathan Slonin Chief Medical Officer | $74k 3,261 shares | -1% | |
| 16Weak | Pacira BioSciences, Inc. | Kristen Williams Chief Administrative Officer | $270k 13,137 shares | -9% | |
| 12Weak | Pacira BioSciences, Inc. | Lauren Riker Senior Vice President, Finance | $83k 4,000 shares | -7% | |
| 1Weak | Pacira BioSciences, Inc. | Lauren Riker Senior Vice President, Finance | $34k 1,416 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.